Tolerability/PoP study in allergic rhinitis after intranasal administration of AZD8848
Study identifier:D0540C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A double-blind, placebo controlled, randomized, parallel group study to investigate the tolerability, safety, pharmacodynamics and pharmacokinetics of repeated weekly doses of AZD8848 administered intranasally to seasonal allergic rhinitis patients
Medical condition
Allergic Rhinitis
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD8848, Placebo
Sex
Male
Actual Enrollment
103
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Sept 2008
Primary Completion Date: 01 Mar 2009
Study Completion Date: 01 Feb 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Aug 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD8848 nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month |
| Placebo Comparator: 2 | Drug: Placebo nasal spray solution. Once weekly intranasal administrations for one month. |
Contacts
Investigators
Principal Investigator
Lennart Greiff
Lund University Hospital
